

Jorge M Blando

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8918120/publications.pdf>

Version: 2024-02-01

25
papers

4,057
citations

567281

15
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

7665
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3032-3041.	7.0	7
2	Abstract 1711: A multi-modal analysis approach leveraging multiplexed spatial phenotyping and multi-omics analysis to better understand the prognostic value of tertiary lymphoid structures in non-small cell lung cancer. <i>Cancer Research</i> , 2022, 82, 1711-1711.	0.9	0
3	<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	82
4	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	27.8	1,421
5	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , 2020, 37, 720-734.e13.	16.8	74
6	Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4599-4599.	1.6	18
7	Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 486-486.	1.6	6
8	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1233-1238.	7.0	260
9	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 1390-1395.	3.4	54
10	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. <i>Clinical Cancer Research</i> , 2019, 25, 3469-3470.	7.0	151
11	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
12	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	9.4	380
13	Levels of CD8+ tumor infiltrating lymphocytes correlate with disease burden in bone marrow of therapy Naïve multiple myeloma patients. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 174-175.	1.3	0
14	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3604-3604.	1.6	8
15	A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4501-4501.	1.6	9
16	A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4551-4551.	1.6	14
17	Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4098-4098.	1.6	3
18	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 189-200.	3.4	102

#	ARTICLE	IF	CITATIONS
19	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	30.7	521
20	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
21	COX-2 mediates pro-tumorigenic effects of PKC μ in prostate cancer. <i>Oncogene</i> , 2018, 37, 4735-4749.	5.9	48
22	Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. <i>Blood</i> , 2018, 132, 906-906.	1.4	13
23	A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation. <i>Blood</i> , 2018, 132, 296-296.	1.4	27
24	Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. <i>Cell Reports</i> , 2017, 19, 375-388.	6.4	72
25	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 6278-6289.	7.0	130